About the Authors
- Floor A. C. Berden
-
Affiliation Department of Gastroenterology and Hepatology, Radboud university medical center, Nijmegen, the Netherlands
- Robert J. de Knegt
-
Affiliation Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands
- Hans Blokzijl
-
Affiliation Department of Gastroenterology and Hepatology, University medical center Groningen, Groningen, the Netherlands
- Sjoerd D. Kuiken
-
Affiliation Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, location West, Amsterdam, the Netherlands
- Karel J. L. van Erpecum
-
Affiliation Department of Gastroenterology and Hepatology, University medical center Utrecht, Utrecht, the Netherlands
- Sophie B. Willemse
-
Affiliation Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands
- Jan den Hollander
-
Affiliation Department of Internal Medicine, Maasstad hospital, Rotterdam, the Netherlands
- Marit G. A. van Vonderen
-
Affiliation Department of Internal Medicine, Medical center Leeuwarden, Leeuwarden, the Netherlands
- Pieter Friederich
-
Affiliation Department of Gastroenterology and Hepatology, Catharina hospital, Eindhoven, the Netherlands
- Bart van Hoek
-
Affiliation Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands
- Carin M. J. van Nieuwkerk
-
Affiliation Department of Gastroenterology and Hepatology, VU university medical center, Amsterdam, the Netherlands
- Joost P. H. Drenth
-
* E-mail: joostphdrenth@cs.com
Affiliation Department of Gastroenterology and Hepatology, Radboud university medical center, Nijmegen, the Netherlands
- Wietske Kievit
-
Affiliation Department for Health Evidence, Radboud university medical center, Nijmegen, the Netherlands
Competing Interests
I have read the journal’s policy and the authors of this manuscript have the following competing interests: F. Berden: no conflict; R. de Knegt has served as a an advisory board member for Gilead, Janssen, BMS, AbbVie, Roche and Norgine, and has received research funding from Janssen, BMS, AbbVie, and Roche; H. Blokzijl: no conflict; S. Kuiken: no conflict; K. van Erpecum has served as an HCV advisory board member for AbbVie, BMS, Gilead and Janssen Cilag, and as a consultant for AbbVie, and has received research funding from Janssen Cilag, Gilead, and AbbVie; S. Willemse has served as a speaker and an advisory board member for AbbVie, Gilead, BMS, Merck, Roche, Janssen, and has received research funding from AbbVie, Gilead, Merck/MSD, and Roche; J. den Hollander: no conflict; M. van Vonderen: no conflict; P. Friederich: no conflict; B. van Hoek has served as a an advisory board member for Gilead, Merck, AbbVie, Norgine, Falk, and Janssen; C. van Nieuwkerk: no conflict; J. Drenth has served as a an advisory board member for Gilead, Janssen, BMS, and AbbVie, and has received research funding from Janssen, AbbVie (this study), dr. Falk, Ipsen, Novartis, Zambon, and Merck; Dr. Kievit: no conflict. This does not alter our adherence to PLOS ONE policies on sharing data and material.
Author Contributions
Conceptualization: FACB JPHD WK. Data curation: FACB WK. Formal analysis: FACB WK. Funding acquisition: JPHD. Investigation: FACB. Methodology: FACB JPHD WK. Project administration: FACB. Resources: FACB RJdK HB SDK KJLvE SBW JdH MGAvV PF BvH CMJvN JPHD. Supervision: JPHD WK. Validation: FACB WK. Writing – original draft: FACB WK JPHD. Writing – review & editing: FACB RJdK HB SDK KJLvE SBW JdH MGAvV PF BvH CMJvN JPHD WK.